All News

Coffee consumption is associated with a lower risk of prostate cancer recurrence and progression, researchers reported.

The risk of women developing kidney stones is rising, as is the number of cases being seen in U.S. emergency departments, while the rate of hospitalization for the disorder has remained stable, recent study findings indicate.

Total annual costs for major health care-associated infections (HAIs) were estimated at $9.8 billion in a recent study, with catheter-associated urinary tract infections representing

For men aged 50–69 years, PSA testing reduces prostate cancer-specific mortality and the incidence of metastatic disease, according to a new multinational consensus statement on early detection of prostate cancer, which also calls for prostate cancer diagnosis to be unlinked from treatment for the disease.

This article examines the relative benefits of robotic surgery in children and special considerations in this patient population, then describes some robotic cases commonly performed for pediatric urologic conditions today.

Most urologists agree that surgical removal of the enlarged portion of the prostate is the most effective and durable way to manage lower urinary tract symptoms in men secondary to BPH. Where it gets interesting is deriving urologic consensus on the best way to achieve that goal.

Epigenetic profiling of prostate biopsies significantly improved the accuracy of predicting cancer in men with negative results, according to a late-breaking abstract presented at the AUA annual meeting in San Diego.

All eligible providers who do not participate in PQRS in 2013 will be subjected to a 1.5% penalty in 2015 and 2% penalty in 2016 and beyond. As you may be aware, there are many ways to participate in PQRS to avoid the 2015 penalty.

One way to structure health care information that you've accumulated in your electronic health record is to use standard instruments to measure the patient experience-often called patient-reported outcomes.

Could bacteria in the lower urinary tract play a role in urologic chronic pelvic pain syndrome (CPPS)? The jury is still out, but the authors of a new study say they weren’t able to find any evidence that germs are at fault.

In a study of African-American men, researchers say they’ve linked two genetic variants to severity of lower urinary tract symptoms related to BPH, giving scientists insight into the higher risk facing African-Americans.

A new study has found that testosterone replacement doesn’t worsen lower urinary tract symptoms related to an enlarged prostate. In fact, many men saw their symptoms improve, apparently with little effect on their prostate gland.

Combining a prostate cancer gene assay with standard risk-stratification factors substantially increased information to guide decision making about active surveillance, a validation study of the assay showed.

Findings from a meta-analysis, including data from five independent patient cohorts, show that a novel genetic test is a powerful prognostic predictor of prostate cancer outcome across diverse clinical settings.

We’re all too familiar with the frustrations that come with the implementation of an EHR. As it turns out, though, practices frequently neglect the part of the system that gives you a return on your investment almost immediately: the patient portal.

The latest products and services from neoSurgical, Wiley-Blackwell, iURO, and USARAD.com.

Urology drugs and devices in the pipeline from AngioDynamics, Tetraphase Pharmaceuticals, Bellicum Pharmaceuticals, Competitive Technologies, Xion Pharmaceuticals, Jubilant Biosys, NewLink Genetics, Exosome Diagnostics, QIAGEN N.V., Aeterna Zentaris, and CureVac GmbH.

The University of Oklahoma College of Medicine, Oklahoma City has appointed Michael Shawn Cookson, MD, MMHC, as professor and chairman of the department of urology. He will hold the Donald Albers Endowed Chair in Urology.

Two new studies provide insights into aggressive prostate cancer that may suggest novel approaches to treatment.

A natural form of sugar could offer a new, noninvasive way to precisely image prostate and other tumors and potentially see whether cancer medication is effective, by means of a new imaging technology.

The tyrosine kinase inhibitors pazopanib (Votrient) and sunitinib (Sutent) had similar benefits in delaying progression of advanced renal cell carcinoma, but the safety profile and many measures of quality of life favored pazopanib, according to data from a recently published multicenter study.

Here’s how some of the ACA’s key provisions are shaping up and what to look for in the months ahead.

The advent of new biomarkers for prostate cancer could help determine the need for observation vs. interventional therapies.

Urologists discuss their preferred treatment approaches for advanced prostate cancer.

Urology Times Editorial Consultant Philip M. Hanno, MD, MPH, interviews Roger Dmochowski, MD, about his institution’s Patient Advocacy Reporting System as well as quality improvement and creating algorithms for appropriate care.

The transition to ICD-10 is not just another thing on urologists’ plates. It’s the main course, and time to prepare for the change is running short.

Prostate cancer aggressiveness may be established when the tumor is formed and does not alter with time, according to a recent study.

After 18 years of follow-up, new findings from the Prostate Cancer Prevention Trial show that the 5-alpha-reductase inhibitor finasteride (Proscar) reduces the risk of prostate cancer by about one-third but has no effect on mortality risk.